FIBROGEN, INC.

FGEN
Delayed Quote. Delayed  - 01/26 04:00:00 pm
48.99USD -1.21%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - Other
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Number of employees : 531 people.
Sales per Business
20182019
USD
(in Million)
%USD
(in Million)
%
Novel Therapeutics 212.96100% 256.58100%
Sales per region
20182019
USD
(in Million)
%USD
(in Million)
%
Europe 112.9253% 132.4051.6%
Japan 100.0047% 122.4847.7%
All Other 0.0400% 1.700.7%
Managers
Name Title
Enrique A. Conterno Chief Executive Officer & Director
James A. Schoeneck Chairman
Pat Cotroneo Chief Financial Officer & Senior VP-Finance
Michael Martinelli Senior Vice President-Technical Development
Elias Kouchakji Senior VP-Clinical Development & Drug Safety
Percy Carter Chief Scientific Officer
Mark Eisner Chief Medical Officer
Kalevi Kurkijärvi Independent Director
Rory B. Riggs Independent Director
Thomas F. Kearns Independent Director
Shareholders
Name Equities %
PRIMECAP Management Co. 9,228,020 10.1%
The Vanguard Group, Inc. 7,134,607 7.84%
Fidelity Management & Research Co. LLC 5,977,100 6.57%
Astellas Pharma Inc. 4,968,367 5.46%
Hillhouse Capital Advisors Ltd. 3,955,787 4.35%
T. Rowe Price Associates, Inc. (Investment Management) 3,850,863 4.23%
Janus Capital Management LLC 3,308,965 3.64%
SSgA Funds Management, Inc. 2,803,092 3.08%
Hillhouse Capital Management Ltd. (Hong Kong) 2,686,196 2.95%
BlackRock Fund Advisors 2,573,761 2.83%
Company contact information
FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158

Phone : +1.415.978.1200
Fax : +1.415.978.1902
Web : http://www.fibrogen.com
Sector Biotechnology & Medical Research - Other
1st jan.Capi. (M$)
FIBROGEN, INC.33.70%4 513
MODERNA, INC.45.35%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.0.65%35 090
SEAGEN INC.-1.43%32 583
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%25 245
INCYTE CORPORATION15.54%22 009
ALNYLAM PHARMACEUTICALS, INC.30.81%20 412
PHARMARON BEIJING CO., LTD.40.91%20 367
BIO-TECHNE CORPORATION7.18%13 607
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.9.48%13 607
CRISPR THERAPEUTICS AG18.37%13 396
QIAGEN N.V.-0.89%12 246
PPD, INC.1.99%12 203
ICON PUBLIC LIMITED COMPANY9.29%11 326
IONIS PHARMACEUTICALS, INC.10.58%8 918
ACADIA PHARMACEUTICALS INC.-3.46%8 577
PRA HEALTH SCIENCES, INC.4.74%8 428
SYNEOS HEALTH, INC.14.27%8 090
UNITED THERAPEUTICS CORPORATION8.60%7 526